1,702 Shares in Johnson & Johnson (NYSE:JNJ) Bought by Martel Wealth Advisors Inc

Martel Wealth Advisors Inc acquired a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,702 shares of the company’s stock, valued at approximately $246,000.

Several other hedge funds have also modified their holdings of JNJ. Culbertson A N & Co. Inc. increased its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Culbertson A N & Co. Inc. now owns 74,871 shares of the company’s stock valued at $10,828,000 after purchasing an additional 559 shares in the last quarter. ZWJ Investment Counsel Inc. increased its position in shares of Johnson & Johnson by 0.8% in the fourth quarter. ZWJ Investment Counsel Inc. now owns 208,857 shares of the company’s stock valued at $30,205,000 after buying an additional 1,760 shares in the last quarter. Tudor Financial Inc. raised its stake in shares of Johnson & Johnson by 17.5% during the 4th quarter. Tudor Financial Inc. now owns 6,436 shares of the company’s stock worth $930,000 after buying an additional 959 shares during the period. Priebe Wealth Holdings LLC grew its stake in Johnson & Johnson by 39.3% in the 4th quarter. Priebe Wealth Holdings LLC now owns 1,817 shares of the company’s stock valued at $263,000 after acquiring an additional 513 shares during the period. Finally, Hoese & Co LLP increased its holdings in Johnson & Johnson by 15.6% in the 4th quarter. Hoese & Co LLP now owns 2,502 shares of the company’s stock worth $362,000 after acquiring an additional 338 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 17th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Barclays reduced their price objective on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $173.27.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $145.39 on Thursday. The company’s 50-day moving average is $148.26 and its two-hundred day moving average is $156.12. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $350.04 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 2.50 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.29 earnings per share. Analysts forecast that Johnson & Johnson will post 9.95 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.41%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.